TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01864018
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01864018
Drug: Ixazomib Citrate
Normalized name: Ixazomib citrate
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00750841
Drug: cediranib
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg cediranib once daily from Days 1-7; cediranib 45 mg plus 600 mg rifampicin from Days 8-14; 45 mg cediranib once daily from Days 15-28; from Day 29 patients may continue on 45 mg cediranib or dose reduce.
Study: NCT04527003
Drug: Cannabidiol (CBD) Extract
Normalized name: cannabidiol (CBD) extract
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabis is a well-known plant that contains more than 500 identified phytochemicals of which over 100 are cannabinoids. The most widely studied is 9-tetrahydrocannabinol (9-THC), which is the major psychoactive component of Cannabis, but Cannabidiol (CBD) has been increasingly favored for its reduced side effect profile and potential health benefits. CBD was first isolated from Cannabis in the 1940s. CBD, unlike 9-THC, does not bind to CB1 and CB2 receptors, which accounts for its lack of typical psychotropic effects, but is still appears to work via alternative mechanisms via the endocannabinoid system.
Study: NCT04527003
Drug: Norethindrone Acetate
Normalized name: Norethindrone Acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethindrone is a form of progesterone, a female hormone important for regulating ovulation and menstruation.
Study: NCT04687163
Drug: HAIC of 130 mg/m² Oxaliplatin, and 5-fu
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hepatic arterial infusion of 130 mg/m² oxaliplatin,leucovorin and 2400 mg/m² 5-FU
Study: NCT04687163
Drug: HAIC of 85 mg/m² Oxaliplatin, and 5-fu
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hepatic arterial infusion of 85 mg/m² oxaliplatin,leucovorin and 2400 mg/m² 5-FU
Study: NCT00559156
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00997581
Drug: apremilast
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: apremilast 20 mg taken twice daily by mouth
Study: NCT01961908
Drug: Proellex
Normalized name: guaiacolsulfonate / hydrocodone bitartrate Oral Solution [Prolex DH]
DrugBank: Telapristone acetate (DB05253)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00646945
Drug: 50% Oxygen/50% Nitrogen premix
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gas flow between 4 to 15 L/min
Study: NCT03334591
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 500mg with Docetaxel 60mg/m2
Study: NCT01254292
Drug: Levonorgestrel IUD (LCS, BAY86-5028)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 18 months with optional extension to 36 months for subjects in this group only.
Study: NCT01254292
Drug: Yasmin (EE30/DRSP, BAY86-5131)
Normalized name: drospirenone
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combined oral contraceptive (COC; Yasmin; 0.03 mg ethinyl estradiol and 3 mg drospirenone); Subjects will start taking COC at / on the day of visit 2 and continue taking one pill / day without any breaks for the entire study duration of 18 months.
Study: NCT01951222
Drug: V0162
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00322907
Drug: Cotrifazid vs mefloquine or quinine+SP
DrugBank: Mefloquine (DB00358)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04117607
Drug: Rezafungin
Normalized name: Rezafungin
DrugBank: Rezafungin (DB16310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.
Study: NCT00004431
Drug: L-baclofen
Normalized name: L-Baclofen
DrugBank: L-Baclofen (DB12098)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00531973
Drug: epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-fluorouracil (500 mg/m²) + epirubicin (90 mg/ m²) + cyclophosphamide (500 mg/ m²) + adjuvant radiation therapy ± endocrinological therapy (FEC90)
Study: NCT02081287
Drug: IP6
Normalized name: Phytic Acid 500 MG Oral Capsule [IP6]
DrugBank: Phytic acid (DB14981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IP6 2,000 -3,000 mg per day given orally in two doses
Study: NCT02081287
Drug: Lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose up to 200 mg per day over 10 weeks
Study: NCT05133752
Drug: Nemonoxacin
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg, oral administration, once daily for 7-10 days.
Study: NCT04117607
Drug: Rezafungin
Normalized name: Rezafungin
DrugBank: Rezafungin (DB16310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rezafungin, 200 mg/vial, is a sterile product supplied as a white to pale yellow lyophilized powder in single-dose glass vials for reconstitution with Sterile Water for Injection, United States Pharmacopeia (USP). The reconstituted product is diluted in 0.9% Sodium Chloride Injection, USP for IV infusion. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredients include excipients of mannitol, polysorbate 80, and histidine.
Study: NCT02901899
Drug: Guadecitabine
Normalized name: Guadecitabine
DrugBank: Guadecitabine (DB11918)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given SC
Study: NCT03434197
Drug: Esflurbiprofen
Normalized name: Esflurbiprofen
DrugBank: Esflurbiprofen (DB16159)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: A plaster containing 40 mg of Esflurbiprofen and 36.2 mg of Japanese Pharmacopoeia mentha oil per patch (10 × 14 cm)
Study: NCT04073498
Drug: SerpinPC
Normalized name: SerpinPC
DrugBank: SerpinPC (DB17698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.
Study: NCT01984411
Drug: Omnipaque
Normalized name: Omnipaque 9
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02589405
Drug: Benzoyl Peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03540212
Drug: Daclatasvir and sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daclatasvir is a DAAs that can inhibit the HCV non-structural (NS) 5A protein when used in combination with other HCV-therapies. It has a linear, non-time-dependent pharmacokinetic profile and nanomolar potency in vitro against HCV genotypes 1-6. It is excreted primarily via faeces, about 88% in an unchanged form while renal excretion accounts for approximately 7% of its elimination.~DOSE OF SOFOSBUVIR: 400 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2.~DOSE OF DACLTASVIR: 60 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2.
Study: NCT00203073
Drug: glatiramer acetate 20 mg
Normalized name: glatiramer acetate 20 MG/ML
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: glatiramer acetate 20 mg
Study: NCT00203073
Drug: glatiramer acetate 20 mg, with mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: glatiramer acetate 20 mg, with mitoxantrone
Study: NCT02653872
Drug: Verapamil
Normalized name: Verapamil
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended release tablet for oral use
Study: NCT02653872
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution
Study: NCT02653872
Drug: Diltiazem
Normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended release capsule
Study: NCT00408460
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00408460
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01191918
Drug: Donepezil and Lithium
Normalized name: donepezil and memantine
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil dose will be started at 5mg/d and increased to 10 mg/d in 1 week.
Study: NCT01191918
Drug: Placebo plus Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03678025
Drug: Abiraterone
Normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03678025
Drug: Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03678025
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given via injection
Study: NCT03678025
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous
Study: NCT03678025
Drug: Flutamide
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03678025
Drug: Goserelin Acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given SC
Study: NCT03678025
Drug: Histrelin Acetate
Normalized name: Histrelin Acetate
DrugBank: Histrelin (DB06788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receive SC
Study: NCT03678025
Drug: Leuprolide Acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive SC or IM
Study: NCT03678025
Drug: Nilutamide
Normalized name: Nilutamide
DrugBank: Nilutamide (DB00665)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03678025
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03678025
Drug: Triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection
Study: NCT00311844
Drug: desloratadine
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02264639
Drug: Pegcetacoplan
Normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Complement (C3) Inhibitor
Study: NCT03062982
Drug: Fluzoparib
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses separated by 7 days.
Study: NCT04633577
Drug: Lidocaine IV
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A bolos of 1.5mg/kg lidocaine will be administered before induction. Then, infusion of 4mg/kg/h lidocaine will maintain during procedure.
Study: NCT01723657
Drug: Ara-C
Normalized name: Ara-C
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Intermediate dose during induction phase to remission.~* High dose during consolidation phase in patients with favorable cytogenetics and leukocyte index below 20.
Study: NCT01723657
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Administration at induction phase to remission, days 0 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatmen arises 30x10e9/L.~* Administration at consolidation phase, days 4 to 6 (3 doses). G-CSF will be interrupted if the leukocyte count during treatment arises 30x10e9/L.
Study: NCT00032955
Drug: Buprenorphine/naloxone
Normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02368197
Drug: paclitaxel (Cardionovum Legflow drug eluting balloon)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Elution of paclitaxel from inflated balloon catheter into vessel wall
Study: NCT00381550
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00381550
Drug: triapine
Normalized name: Triapine
DrugBank: Triapine (DB11940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03760588
Drug: Sacubitril/valsartan
Normalized name: SACUBITRIL/VALSARTAN
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Target dose 97/103 mg b.i.d .
Study: NCT02314377
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab dosing of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).
Study: NCT00091598
Drug: Ambrisentan
Normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02978326
Drug: SAGE-217 15/20 mg Oral Solution
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAGE-217, 15 mg oral solution, BID for Days 1 to 2 followed by 20 mg oral solution BID for Days 3 to 14. If not tolerated, 15 mg for the rest of study (Days 3 to 14).
Study: NCT02978326
Drug: SAGE 217 30 mg Capsules
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAGE-217, 30 mg, capsules, orally, once daily, for up to 14 days.
Study: NCT00837356
Drug: turoctocog alfa
Normalized name: Turoctocog alfa
DrugBank: Turoctocog alfa (DB09109)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: After a washout period of 4 days, subjects will subsequently receive turoctocog alfa (recombinant factor VIII (N8)) at a dose of 50 IU/kg body weight in the second session
Study: NCT03317613
Drug: Qutenza
Normalized name: Qutenza
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients suffering from neuropathic pain will receive patch of capsaicin (qutenza) on the painful zones. Three months after the first application, patients will be allowed to receive another patch if necessary. They will be able to receive one every three months. They will be followed in the study during one year after the first patch application.
Study: NCT02010411
Drug: Prolastin (drug)
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outcomes compared to saline or no intervention in each subject.
Study: NCT04195997
Drug: Bivalirudin
Normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients would be given anticoagulant therapy with bivalirudin in left atrial appendage occusion.
Study: NCT00151294
Drug: escitalopram oxalate antidepressant
Normalized name: Escitalopram Oxalate
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01842451
Drug: VX-135
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01842451
Drug: Daclatasvir
Normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01775761
Drug: Period 3
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
Study: NCT00991198
Drug: Topical oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% concentration of Topical oxygen
Study: NCT00991198
Drug: Topical oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% concentration topical oxygen
Study: NCT03922477
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered to participants by IV infusion at a fixed dose starting on Day 22 of Cycle 1. In subsequent cycles (Cycles 2 and beyond), IV atezolizumab will be given every 2 weeks (Q2W) on Days 8 and 22 of each 28-day cycle.
Study: NCT03922477
Drug: Hu5F9-G4
Normalized name: Anti-cd47 monoclonal antibody hu5f9-g4
DrugBank: Magrolimab (DB16225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two priming doses of 1 mg/kg of Hu5F9-G4 will be administered to participants by continuous IV infusion on Days 1 and 4 of Cycle 1, followed by loading doses of 15 mg/kg IV on Day 8 and 30 mg/kg IV on Day 11. Starting on Day 15 of Cycle 1, Hu5F9-G4 maintenance will be given by IV infusion at a dose of 30 mg/kg once a week (QW) of each 28-day cycle. Dosing for de-escalation, if needed: Hu5F9-G4 will be given as two priming doses of 1 mg/kg IV on Days 1 and 4, followed by loading doses of 10 mg/kg IV on Day 8 and 15 mg/kg on Day 11. Starting on Day 15, maintenance treatment with Hu5F9-G4 will be given by IV infusion at a dose of 15 mg/kg once a week (QW).
Study: NCT03523234
Drug: neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoposide with cisplatin/carboplatin, undergoing in prior to the surgery
Study: NCT01272557
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib 400 mg bid (oral) continuously
Study: NCT04104646
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral morphine administration at starting dose of 0.07 mg/kg q4
Study: NCT04104646
Drug: Morphine matched placebo
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral morphine matched placebo administration
Study: NCT00788957
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab for intravenous infusion
Study: NCT00788957
Drug: Ganitumab
Normalized name: Ganitumab
DrugBank: Ganitumab (DB12205)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganitumab for intravenous infusion
Study: NCT00788957
Drug: Rilotumumab
Normalized name: Rilotumumab
DrugBank: Rilotumumab (DB11972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilotumumab for intravenous infusion
Study: NCT00545558
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg tablet taken orally daily
Study: NCT00545558
Drug: Emtricitabine/Tenofovir disoproxil fumarate
Normalized name: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally daily
Study: NCT02486796
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preparation of coenzyme Q10
Study: NCT02687009
Drug: Niclosamide
Normalized name: niclosamide
DrugBank: Niclosamide (DB06803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Niclosamide will be taken orally in the morning of each day from day 1-7 prior to surgery for resection of primary tumor. Niclosamide tablets must be chewed well prior to swallowing.
Study: NCT03387098
Drug: Aldoxorubicin HCl
Normalized name: Doxorubicin Hydrochloride
DrugBank: Aldoxorubicin (DB06013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldoxorubicin hydrochloride
Study: NCT03387098
Drug: nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
Study: NCT03387098
Drug: lovaza
Normalized name: Lovaza
DrugBank: Omega-3-acid ethyl esters (DB09539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3-acid ethyl esters
Study: NCT03387098
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
Study: NCT00620347
Drug: sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sunitinib (50mg/day, 4weeks on, 2 weeks off) Repeat every 6 weeks. Treatment will continue until disease progression, unacceptable toxicity, or patients' refusal.
Study: NCT01180647
Drug: Extended-Release Naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 380mg IM XR-NTX injection one week prior to release from jail; a second XR-NTX 380mg IM injection is offered 4 weeks later (monthly).
Study: NCT01273610
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 250 mg tablets
Study: NCT01273610
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous injection
Study: NCT01626859
Drug: MP-214 3mg
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who meet eligibility criteria will be administered a once daily oral 3mg of MP-214 for twelve weeks.
Study: NCT01626859
Drug: MP-214 6mg
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who meet eligibility criteria will be administered a once daily oral 6mg of MP-214 for twelve weeks.
Study: NCT01626859
Drug: MP-214 9mg
Normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients who meet eligibility criteria will be administered a once daily oral 9mg of MP-214 for twelve weeks.
Study: NCT01108900
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tables, 25,50,100 mg, on demand, 1 month
Study: NCT02740634
Drug: C-11 PiB
Normalized name: C-11 PiB
DrugBank: Pittsburgh Compound B (DB15161)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amyloid binding agent
Study: NCT02522715
Drug: Cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02522715
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO